Essais ouverts

• NCT07711574Inconnu

  Prevalence of Depression Among Patients With Alopecia Areata

  Sohag University · Participants visés: 100 · sept. 2027 · Égypte

• NCT07529977Phase 3→ Minoxidil (topical)

  Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.

  Eurofarma Laboratorios S.A. · Participants visés: 372 · janv. 2027

• NCT07758400Inconnu

  A Study on the Efficacy and Safety of Microneedling for Male Androgenetic Alopecia

  Cheng Zhou · Participants visés: 190 · janv. 2027 · Chine

• NCT07303322Phase 3→ N1087

  Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)

  Eurofarma Laboratorios S.A. · Participants visés: 372 · janv. 2027

• NCT07739147Phase 0

  Comparing Standard Platelet-Rich Plasma and Light-Enhanced Platelet-Rich Plasma for Treating Hair Loss in Androgenetic Alopecia: A Randomized Controlled Trial

  Kimberly Meathrel · Participants visés: 30 · déc. 2026

• NCT07482423Phase 1/2

  XVIE to Treat Androgenetic Alopecia (AGA)

  Restore Biologics Holdings, Inc. dba Xtressé · Participants visés: 30 · déc. 2026 · États-Unis

• NCT07705217Inconnu

  The Role of Gut and Skin Microbiota in Alopecia Areata

  Polyclinic GrandMed · Participants visés: 30 · oct. 2026 · Croatie

• NCT03474718Phase 0

  Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia

  Wake Forest University Health Sciences · Participants visés: 16 · oct. 2026 · États-Unis

• NCT07762443Phase 1→ VC005

  A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata

  Jiangsu vcare pharmaceutical technology co., LTD · Participants visés: 24 · sept. 2026 · Chine

• NCT07637071Inconnu

  Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia

  Restore Biologics Holdings, Inc. dba Xtressé · Participants visés: 48 · sept. 2026 · États-Unis

• NCT07734870Phase 2

  Tirzepatide for Treatment of CCCA

  Johns Hopkins University · Participants visés: 20 · sept. 2026 · États-Unis

• NCT07671157Phase 2→ Delgocitinib (LEO 124249)

  Phase 2 Open Label Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)

  Maryanne Makredes Senna · Participants visés: 30 · sept. 2026 · États-Unis

• NCT07474558Phase 2

  SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates

  Jules Bordet Institute · Participants visés: 102 · sept. 2026 · Belgique

• NCT07772492Phase 3🇫🇷 France→ Upadacitinib (Rinvoq)

  A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata

  AbbVie · Participants visés: 300 · août 2026 · États-Unis, Australie, France, Israël

• NCT07749716Phase 2→ VC005

  Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata

  Jiangsu vcare pharmaceutical technology co., LTD · Participants visés: 120 · août 2026 · Chine

• NCT07716748Inconnu

  For an Investigator-led Hair Study Comparing Between Healthy and Hair Loss Volunteers

  National Skin Centre · Participants visés: 66 · août 2026

• NCT07748169Inconnu

  An Observational Study of Patients With Dermatologic Disease

  Target PharmaSolutions, Inc. · Participants visés: 2000000 · août 2026 · États-Unis

• NCT07733765Phase 3→ Ritlecitinib (Litfulo)

  A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

  Pfizer · Participants visés: 336 · juil. 2026 · États-Unis

• NCT07516561Phase 3→ Eniagor

  Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia

  Apsen Farmaceutica S.A. · Participants visés: 336 · juil. 2026 · Brésil

• NCT07594678Phase 2→ Minoxidil (topical)

  Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer Patients

  Ohio State University Comprehensive Cancer Center · Participants visés: 50 · juil. 2026 · États-Unis

• NCT07696585Inconnu

  New Topical Treatment in Patchy Alopecia Areata

  Sohag University · Participants visés: 60 · juin 2026

• NCT07617597Phase 3→ Deuruxolitinib (Leqselvi)

  Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata

  Sun Pharma Japan Limited · Participants visés: 78 · juin 2026 · Japon

• NCT07733063Inconnu

  Serum Ferroptosis Biomarkers (GPX4, MDA) in Alopecia Areata

  Istanbul Training and Research Hospital · Participants visés: 156 · juin 2026 · Turquie

• NCT07508488Phase 2→ Deucravacitinib

  Deucravacitinib in the Treatment of Cicatricial Alopecias

  Icahn School of Medicine at Mount Sinai · Participants visés: 20 · mai 2026 · États-Unis

• NCT07487948Phase 2→ Delgocitinib (LEO 124249)

  Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

  Icahn School of Medicine at Mount Sinai · Participants visés: 30 · mai 2026 · États-Unis

• NCT07536100Inconnu→ Minoxidil (topical)

  VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia

  Institute of Dermatology, Thailand · Participants visés: 80 · mai 2026 · Thaïlande

• NCT06648850Phase 2/3→ DA-001 / DA-002 / DA-005

  Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth

  Applied Biology, Inc. · Participants visés: 1120 · mai 2026

• NCT07580521Inconnu

  Microneedling for Androgenic Alopecia: a Clinical Study

  Taipei Medical University WanFang Hospital · Participants visés: 25 · mai 2026

• NCT07693244Phase 2

  Exosome Therapy for Male Androgenetic Alopecia

  Zhang Han · Participants visés: 120 · avr. 2026 · Chine

• NCT07340671Inconnu

  Facial Papules in Frontal Fibrosing Alopecia (FFA)

  University of Miami · Participants visés: 10 · avr. 2026 · États-Unis

• NCT07294313Inconnu

  Harnessing Artificial Intelligence for Diagnosing Androgenetic Alopecia: A Training and Validation Study

  Cairo University · Participants visés: 400 · avr. 2026 · Égypte

• NCT07554222Phase 1

  Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration

  Innovent Biologics (Suzhou) Co. Ltd. · Participants visés: 160 · avr. 2026 · Chine

• NCT07402330Phase 0→ DA-001 / DA-002 / DA-005

  Pharmacokinetic Study of DA-020

  Applied Biology, Inc. · Participants visés: 60 · avr. 2026 · Brésil, Italie

• NCT07397325Phase 1/2→ DA-001 / DA-002 / DA-005

  Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia

  Applied Biology, Inc. · Participants visés: 60 · avr. 2026 · Brésil, Italie

• NCT07533006Phase 2

  A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

  Eli Lilly and Company · Participants visés: 60 · avr. 2026 · États-Unis, Canada, Chine, Pays-Bas

• NCT07268534Phase 2

  Biologics in Folliculitis Decalvans : an Adaptative Trial Research

  Assistance Publique - Hôpitaux de Paris · Participants visés: 120 · avr. 2026

• NCT07499713Inconnu

  Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia Areata

  Istanbul Training and Research Hospital · Participants visés: 90 · avr. 2026 · Turquie

• NCT07453238Approuvé

  Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata

  Hayat Abad Medical Complex, Peshawar · Participants visés: 60 · avr. 2026

• NCT07518342Approuvé

  The Effect of Nanofat Injection on Androgenetic Alopecia

  Assiut University · Participants visés: 60 · avr. 2026 · Égypte

• NCT07490327Phase 1/2→ Dutasteride (Avodart / Zagallo)

  Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia

  Moogene Medi Co., Ltd · Participants visés: 30 · avr. 2026 · Corée du Sud

• NCT07435012Phase 3→ TH07

  Androgenic Alopecia TH07 Clinical Trial

  Triple Hair Inc · Participants visés: 420 · avr. 2026 · Canada

• NCT07484061Inconnu

  Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists

  Olistic Research Labs S.L. · Participants visés: 40 · mars 2026 · Espagne

• NCT07459933Approuvé→ Minoxidil (topical)

  Topical Methotrexate vs Minoxidil for Localized Alopecia Areata

  Jinnah Postgraduate Medical Centre · Participants visés: 268 · mars 2026

• NCT07603544Inconnu

  Multi-Omics Insights Into Androgenetic Alopecia

  The First Affiliated Hospital of Xinxiang Medical College · Participants visés: 12 · mars 2026 · Chine

• NCT07422376Inconnu

  Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands Region

  Charles Mays · Participants visés: 100 · mars 2026 · États-Unis

• NCT07588243Inconnu

  A Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth

  CynosureLutronic · Participants visés: 44 · févr. 2026 · États-Unis

• NCT07406204Approuvé

  Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)

  Hayat Abad Medical Complex, Peshawar · Participants visés: 78 · févr. 2026

• NCT07368842Inconnu

  Scalp Hair Metabolomics in Severe Obesity

  Singapore General Hospital · Participants visés: 60 · févr. 2026 · Singapour

• NCT07563036Inconnu→ Minoxidil (topical)

  JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil

  Kasr El Aini Hospital · Participants visés: 25 · févr. 2026 · Égypte

• NCT07370519Phase 2

  Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia

  Shenzhen People's Hospital · Participants visés: 388 · janv. 2026 · Chine

• NCT07618195Phase 1/2→ Epibiotech dermal papilla cell therapy

  Study of EPI-001 in Patients With Androgenetic Alopecia

  Epibiotech · Participants visés: 42 · janv. 2026 · Corée du Sud

• NCT07242638Phase 2

  Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

  Icahn School of Medicine at Mount Sinai · Participants visés: 56 · janv. 2026 · États-Unis

• NCT07429253Phase 1/2

  Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients

  PT. Prodia Stem Cell Indonesia · Participants visés: 40 · janv. 2026 · Indonésie

• NCT07335367Phase 2

  PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study

  Nanfang Hospital, Southern Medical University · Participants visés: 76 · janv. 2026 · Chine

• NCT07336641Inconnu

  LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice

  Fondazione ISIDE · Participants visés: 20000 · janv. 2026 · Italie

• NCT07502976Inconnu→ Minoxidil (topical)

  Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia

  Kasr El Aini Hospital · Participants visés: 60 · janv. 2026 · Égypte

• NCT07287579Inconnu

  Comparison Between Platelet Rich Plasma and Nanofat as an Adjuvant Therapy in HairTransplantation

  Sohag University · Participants visés: 30 · janv. 2026

• NCT07273799Phase 3→ Minoxidil (topical)

  Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia

  Sheikh Zayed Federal Postgraduate Medical Institute · Participants visés: 200 · déc. 2025

• NCT07311564Phase 2

  A Study of LAD603 in Adults With Alopecia Areata

  Almirall, S.A. · Participants visés: 136 · déc. 2025 · États-Unis

• NCT07250997Inconnu

  PALLAS Laser for Skin Diseases

  Szeged University · Participants visés: 50 · déc. 2025 · Hongrie

• NCT06946550Inconnu

  Non-Ablative Laser to Treat Scarring Alopecia With Hair Follicle Gene Expression Analysis

  Montefiore Medical Center · Participants visés: 5 · déc. 2025 · États-Unis

• NCT07327359Phase 1/2

  A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia

  Olix Pharmaceuticals, Inc. · Participants visés: 158 · déc. 2025 · Australie

• NCT07317544Phase 1/2

  Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia

  Absci Pty Ltd. · Participants visés: 227 · déc. 2025 · Australie

• NCT07248410Inconnu

  A Split-Scalp Study Evaluating the Efficacy and Safety of Fractional Laser Therapy With and Without Exosomes in the Treatment of Androgenetic Alopecia

  Chang Gung Memorial Hospital · Participants visés: 30 · nov. 2025 · Taïwan

• NCT07144345Phase 3

  Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

  Sun Pharmaceutical Industries, Inc. · Participants visés: 160 · nov. 2025 · États-Unis

• NCT07373054Inconnu

  Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia

  Fujian Medical University Union Hospital · Participants visés: 18 · nov. 2025 · Chine

• NCT07381556Approuvé

  Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study

  Erasmus Medical Center · Participants visés: 50 · nov. 2025 · Pays-Bas

• NCT07190534Inconnu

  The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)

  Erasmus Medical Center · Participants visés: 50 · nov. 2025 · Pays-Bas

• NCT07205159Phase 1

  A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.

  Forte Biosciences, Inc. · Participants visés: 32 · oct. 2025 · Australie, Nouvelle-Zélande

• NCT07107841Inconnu

  Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)

  Acorn Biolabs Inc. · Participants visés: 60 · oct. 2025 · États-Unis

• NCT06762548Phase 3→ DA-001 / DA-002 / DA-005

  Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia

  Applied Biology, Inc. · Participants visés: 140 · oct. 2025 · Italie

• NCT06998433Approuvé

  Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia

  Baylor College of Medicine · Participants visés: 56 · sept. 2025 · États-Unis

• NCT07221773Inconnu

  Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair

  Restore Biologics Holdings, Inc. dba Xtressé · Participants visés: 15 · sept. 2025 · États-Unis

• NCT07203599Phase 1/2

  A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes

  Shenzhen People's Hospital · Participants visés: 59 · sept. 2025 · Chine

• NCT07029828Phase 3🇫🇷 France→ Ritlecitinib (Litfulo)

  A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

  Pfizer · Participants visés: 140 · sept. 2025 · États-Unis, Chine, Tchéquie, France

• NCT07136467Inconnu🇫🇷 France

  A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

  AbbVie · Participants visés: 2795 · sept. 2025 · Argentine, Canada, Colombie, Tchéquie

• NCT07112586Phase 1/2

  Evaluation of Exosomes Injection in Treatment of Male Androgenetic Alopecia: Clinical and Immunohistochemical Study

  Ain Shams University · Participants visés: 15 · août 2025 · Égypte

• NCT07152119Inconnu→ Ritlecitinib (Litfulo)

  A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.

  Pfizer · Participants visés: 3000 · août 2025 · Corée du Sud

• NCT06747611Phase 2

  Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata

  University of Minnesota · Participants visés: 40 · août 2025 · États-Unis

• NCT07049328Phase 1

  HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata

  HCW Biologics · Participants visés: 30 · août 2025 · États-Unis

• NCT07133308Phase 3→ Deuruxolitinib (Leqselvi)

  Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

  Sun Pharmaceutical Industries, Inc. · Participants visés: 355 · août 2025 · États-Unis, Canada

• NCT06869252Phase 1/2

  Autologous Adipose Cells Therapy

  CERM INC. · Participants visés: 40 · août 2025 · États-Unis

• NCT06998680Inconnu

  6-Month Trial of Chinese Herbal Treatments for Hair Loss and Gray Hair

  Vita Green Pharmaceutical (H.K.) Ltd. · Participants visés: 152 · juil. 2025 · Chine

• NCT07056933Inconnu→ Minoxidil (topical)

  Effect of Minoxidil Solution Iontophoresis on Androgenic Alopecia

  Cairo University · Participants visés: 25 · juil. 2025 · Égypte

• NCT07033845Phase 0→ DA-001 / DA-002 / DA-005

  Pharmacokinetic Study of Topical Phenylephrine

  Applied Biology, Inc. · Participants visés: 24 · juin 2025 · Italie

• NCT07018349Inconnu

  Low Dose Oral Minoxdil in Androgenic Alopecia

  Jinnah Postgraduate Medical Centre · Participants visés: 76 · juin 2025 · Pakistan

• NCT07012486Phase 0

  Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia

  Shanghai Zhongshan Hospital · Participants visés: 30 · juin 2025 · Chine

• NCT06562894Phase 2→ SYHX1901

  Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients

  CSPC Ouyi Pharmaceutical Co., Ltd. · Participants visés: 156 · mai 2025

• NCT07041489Inconnu

  Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair

  The Center for Clinical and Cosmetic Research · Participants visés: 85 · mai 2025 · États-Unis

• NCT06926023Inconnu

  1550nm Non-ablative Fractional Vs 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss

  Goldman, Butterwick, Fitzpatrick and Groff · Participants visés: 10 · mai 2025 · États-Unis

• NCT06916793Phase 3→ CKD-843

  A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

  Chong Kun Dang Pharmaceutical · Participants visés: 288 · avr. 2025 · Corée du Sud

• NCT06873945Phase 3→ Ritlecitinib (Litfulo)

  A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

  Pfizer · Participants visés: 1330 · avr. 2025 · États-Unis, Canada, Chine, Tchéquie

• NCT07224555Inconnu

  Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair

  Restore Biologics Holdings, Inc. dba Xtressé · Participants visés: 60 · mars 2025 · États-Unis

• NCT06826196Phase 1/2

  A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

  Aldena Therapeutics · Participants visés: 24 · mars 2025 · États-Unis, Canada

• NCT07080931Phase 3→ Minoxidil (topical)

  Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia

  Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Participants visés: 294 · févr. 2025 · Chine

• NCT06885112Inconnu

  Clinical Study to Evaluate the Improvement in Hair Loss in Skin of Color Treated With Fractional Non-Ablative Laser

  Lumenis Be Ltd. · Participants visés: 40 · févr. 2025 · États-Unis

• NCT06818370Inconnu

  The Effect of Coconut Oil on Alopecia

  Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital · Participants visés: 86 · févr. 2025 · Turquie

• NCT06826001Phase 2→ Topical finasteride

  Various Procedural Treatment Options for Androgenetic Alopecia

  Sheikh Zayed Medical College · Participants visés: 190 · févr. 2025 · Pakistan

• NCT06801821Inconnu

  Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis

  Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Participants visés: 400 · févr. 2025 · Italie

• NCT06797310Phase 2→ Baricitinib (Olumiant)

  Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study

  National Taiwan University Hospital · Participants visés: 30 · janv. 2025 · Taïwan

• NCT06501924Phase 3→ DA-001 / DA-002 / DA-005

  Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss

  Applied Biology, Inc. · Participants visés: 516 · janv. 2025

• NCT05824065Phase 3→ OMA102

  Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss

  EMS · Participants visés: 504 · janv. 2025 · Brésil

• NCT06764329Phase 1/2

  The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia.

  National Institute of Blood and Marrow Transplant (NIBMT), Pakistan · Participants visés: 70 · déc. 2024 · Pakistan

• NCT06786078Inconnu

  The Lily Device Trial

  Luminate Medical, Inc. · Participants visés: 85 · déc. 2024 · États-Unis

• NCT06292533Inconnu

  Effectiveness of Ultrapulse for the Treatment of Androgenic Alopecia Among Malaysian: A Quasi-experimental Study

  Universiti Tunku Abdul Rahman · Participants visés: 92 · déc. 2024 · Malaisie

• NCT05484973Inconnu

  Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss

  Cooler Heads Care Inc. · Participants visés: 99 · nov. 2024 · États-Unis

• NCT06590779Inconnu

  Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss

  Cosmetique Active International · Participants visés: 140 · nov. 2024

• NCT06646146Inconnu

  Study on the Efficacy of Autologous Fat Grafting in Improving Hair Transplantation Outcomes for Patients With Localized Scleroderma-Related Alopecia

  Nanfang Hospital, Southern Medical University · Participants visés: 40 · oct. 2024

• NCT05888922Phase 3→ Minoxidil (low-dose oral)

  Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

  Industrial Farmacéutica Cantabria, S.A. · Participants visés: 520 · oct. 2024 · Allemagne

• NCT06622824Phase 2/3→ Pyrilutamide

  To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia

  Suzhou Kintor Pharmaceutical Inc, · Participants visés: 756 · oct. 2024 · Chine

• NCT06841458Inconnu

  Six-Month Single-Blind, Placebo-Controlled Study of a Dietary Supplement Supplement on Hair Growth in 45 Volunteers

  Industrial Farmacéutica Cantabria, S.A. · Participants visés: 45 · oct. 2024 · Espagne

• NCT06399783Approuvé

  Topical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata

  Assiut University · Participants visés: 54 · oct. 2024 · Égypte

• NCT06560385Inconnu

  Alleviation of Alopecia in Breast Cancer Patient Using Synbiotics Formula

  GenieBiome Limited · Participants visés: 40 · sept. 2024 · Hong Kong

• NCT06104839Phase 2

  Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata

  NEXTGEN Bioscience · Participants visés: 73 · sept. 2024 · Corée du Sud

• NCT06558565Inconnu

  Efficacy of Stromal Vascular Fraction Versus Platelet Rich Plasma in Treatment of Androgenitic Alopecia

  Kasr El Aini Hospital · Participants visés: 20 · août 2024 · Égypte

• NCT06603194Inconnu

  Benefit of Bovine or Marine Collagen Vs. Placebo on Skin, Hair, Nails and Whole Body Health in Healthy Adults

  Ancient + Brave · Participants visés: 90 · août 2024 · Royaume-Uni

• NCT06564805Inconnu

  Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata

  Universidad Autonoma de Nuevo Leon · Participants visés: 30 · août 2024 · Mexique

• NCT06531109Inconnu🇫🇷 France→ Ritlecitinib (Litfulo)

  Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

  Pfizer · Participants visés: 450 · août 2024 · États-Unis, Chine, France, Italie

• NCT06573593Inconnu

  Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

  Second Affiliated Hospital, Zhejiang University, School of Medicine · Participants visés: 150 · juil. 2024 · Chine

• NCT05866562Phase 2

  Dupilumab in the Treatment of Pediatric Alopecia Areata

  Icahn School of Medicine at Mount Sinai · Participants visés: 76 · juil. 2024 · États-Unis

• NCT06562270Inconnu

  CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

  CorEvitas · Participants visés: 1500 · mars 2024 · États-Unis

• NCT06326359Inconnu

  Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia

  Sohag University · Participants visés: 40 · mars 2024

• NCT06360718Inconnu

  Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.

  Children's Hospital Los Angeles · Participants visés: 140 · févr. 2024 · États-Unis

• NCT06283316Inconnu

  Systemic Treatments for Alopecia Areata Registry

  Erasmus Medical Center · Participants visés: 10000 · janv. 2024 · Pays-Bas

• NCT06327581Inconnu

  Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata

  Zagazig University · Participants visés: 88 · déc. 2023 · Égypte

• NCT05460611Inconnu

  1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia

  Montefiore Medical Center · Participants visés: 10 · déc. 2023 · États-Unis

• NCT07079657Inconnu

  Thulium Laser and Growth Factors for Androgenetic Alopecia

  Universitätsklinikum Hamburg-Eppendorf · Participants visés: 30 · déc. 2023 · Allemagne

• NCT06955702Inconnu

  Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients

  University of Salamanca · Participants visés: 120 · nov. 2023 · Espagne

• NCT06012240Phase 3🇫🇷 France→ Upadacitinib (Rinvoq)

  A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

  AbbVie · Participants visés: 1500 · oct. 2023 · États-Unis, Argentine, Australie, Belgique

• NCT06046651Inconnu

  Blood Specimen Collection For Laboratory Assay Research

  Roman Health Ventures Inc. · Participants visés: 10000 · août 2023 · États-Unis

• NCT05928169Inconnu

  Determinants of Chronic Inflammatory Skin Disease Trajectories

  University Hospital Schleswig-Holstein · Participants visés: 1000 · mai 2023 · Allemagne

• NCT05551793Phase 2

  Regeneron AA Multicenter (Dupilumab)

  Emma Guttman · Participants visés: 76 · avr. 2023 · États-Unis

• NCT05417308Phase 0→ Minoxidil (low-dose oral)

  Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

  Ohio State University Comprehensive Cancer Center · Participants visés: 50 · mars 2023 · États-Unis

• NCT05723198Phase 3🇫🇷 France→ Baricitinib (Olumiant)

  A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

  Eli Lilly and Company · Participants visés: 595 · févr. 2023 · États-Unis, Argentine, Australie, Canada

• NCT04594018Phase 3→ Finasteride (Propecia)

  Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia

  EMS · Participants visés: 190 · févr. 2023 · Brésil

• NCT05398809Phase 2

  Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

  National Institute of Allergy and Infectious Diseases (NIAID) · Participants visés: 70 · janv. 2023 · États-Unis

• NCT05745389Inconnu

  CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry

  CorEvitas · Participants visés: 5000 · oct. 2022 · États-Unis

• NCT05213936Inconnu

  Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color

  Montefiore Medical Center · Participants visés: 41 · oct. 2022 · États-Unis

• NCT05177289Inconnu

  Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Alopecia

  Jessa Hospital · Participants visés: 72 · févr. 2022 · Belgique

• NCT04986579Phase 2

  Scalp Cooling in MBC

  Dana-Farber Cancer Institute · Participants visés: 120 · oct. 2021 · États-Unis

• NCT04764331Inconnu

  A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia

  Wake Forest University Health Sciences · Participants visés: 5 · juil. 2021 · États-Unis

• NCT04764357Inconnu

  Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors

  St. Jude Children's Research Hospital · Participants visés: 40 · juin 2021 · États-Unis

• NCT03976622Inconnu🇫🇷 France

  Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata

  University Hospital, Bordeaux · Participants visés: 450 · janv. 2020 · France

• NCT04014413Inconnu

  Safety and Efficacy of Fecal Microbiota Transplantation

  Chinese University of Hong Kong · Participants visés: 450 · juil. 2019 · Hong Kong

• NCT04207931Approuvé

  Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study

  Wake Forest University Health Sciences · Participants visés: 250 · avr. 2018 · États-Unis

• NCT05938569Inconnu

  Computer-Assisted Hair Restoration Study Using ARTAS System

  Venus Concept · Participants visés: 150 · nov. 2016 · États-Unis

Lister un essai n'est pas une invitation à y participer. Les critères, les risques et les coûts varient énormément — parlez-en d'abord à votre médecin.